satralizumab news

All news on satralizumab (also known as Enspryng): plants, production capacities, investments and involved companies.

30 June 2026

Roche’s Enspryng wins FDA Priority Review for at‑home subcutaneous TED treatment

FDA accepted an sBLA and granted Priority Review for the first at‑home subcutaneous option for thyroid eye disease; decision expected 15 Oct 2026.

Who will be producing satralizumab in the future?

Find out with chemXplore Alpha

Learn more